Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Echinomycin is a cell-permeable hypoxia-inducible factor-1 (HIF-1) DNA-binding activity inhibitor. Echinomycin selectively inhibits the cancer stem cells (CSCs; IC50: 29.4 pM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | 35 days | $ 243.00 | |
5 mg | 35 days | $ 882.00 |
Description | Echinomycin is a cell-permeable hypoxia-inducible factor-1 (HIF-1) DNA-binding activity inhibitor. Echinomycin selectively inhibits the cancer stem cells (CSCs; IC50: 29.4 pM). |
In vitro | Echinomycin potently inhibits hypoxic induction of luciferase expression in U251-HRE in a dose-dependent fashion (EC50: 1.2 nM). Echinomycin (0-10 nM; 16 hours; U251 cells) treatment obviously inhibits hypoxia-induced VEGF mRNA expression in a dose-dependent fashion [1]. |
In vivo | HIF1α maintains mouse lymphoma cancer stem cells (CSCs) by repressing a negative feedback loop in the Notch pathway. Echinomycin (10 μg/kg; i.v.; for 40 days; NOD-SCID mice) treatment, by preferential elimination of CSCs, which efficiently eradicates mouse lymphoma and serially transplantable human acute myeloid leukemia (AML) in the xenogeneic model [2]. |
Synonyms | Quinomycin A, NSC-13502 |
Molecular Weight | 1101.26 |
Formula | C51H64N12O12S2 |
CAS No. | 512-64-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Echinomycin 512-64-1 Others Quinomycin A NSC-13502 NSC13502 NSC 13502 inhibitor inhibit